European Medicines Agency: mRNA COVID-19 vaccine is not associated with autoimmune hepatitis
- United States has begun to purchase monkeypox vaccines
- FDA may revise approval path to avoid some procedures abused by pharmaceutical companies
- Bayer terminates $670 million CAR-T partnership with Atara after patient death
- How much do cancer patients pay for CAT-T immunotherapy?
- Highly pathogenic bird flu outbreak: Watch out for ‘super-spreader’ bird species
- CanSino’s COVID-19 vaccine is included in WHO’s emergency use list (EUL)
European Medicines Agency: mRNA COVID-19 vaccine is not associated with autoimmune hepatitis
- Unexplained acute hepatitis in children may be related to COVID superantigens
- How long can the patient live after heart stent surgery?
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
European Medicines Agency: mRNA COVID-19 vaccine is not associated with autoimmune hepatitis.
Recently, a study on “COVID-19 vaccine may cause a rare T cell-mediated autoimmune hepatitis” published in the Journal of Hepatology, a journal in the field of liver disease concerns about adverse reactions.
The paper, which was finalized on March 31, 2022, refers to a case report in Germany of a 52-year-old man who developed a bimodal flare of acute hepatitis after 2 doses of mRNA vaccine.
In this regard, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) announced on April 8 that there is currently no evidence to support a causal relationship between the mRNA COVID-19 vaccine and autoimmune hepatitis (AIH), and no update is currently required. Product information for vaccines.
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) discussed the case at its April 2-7 meeting and subsequently released its latest minutes.
Autoimmune hepatitis (AIH) is a very rare chronic progressive liver inflammatory disease mediated by an autoimmune response, according to the PRAC meeting minutes. The PRAC came to this conclusion after reviewing literature data, AIH cases reported to the EudraVigilance database and further data provided by marketing authorisation holders.
The European Medicines Agency (EMA) said it will continue to closely monitor any new situation reports and take appropriate measures if necessary.
(source:internet, reference only)
Disclaimer of medicaltrend.org
